AI-generated illustration; not a photograph of the reported event.
- calendar_today October 13, 2026
Pennsylvania Takes Action on Rising Insulin Prices
On Friday, Pennsylvania Attorney General Dave Sunday filed a lawsuit against several major insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of conspiring to dramatically inflate insulin prices. The lawsuit alleges that these companies' actions have directly harmed the 1.3 million Pennsylvanians with diabetes and another 3.5 million with prediabetes, forcing some individuals to ration their vital medication or go without adequate nutrition to control blood sugar levels.
Allegations of Price Collusion Among Pharmaceutical Companies
The lawsuit names over a dozen defendants, including prominent insulin manufacturers Eli Lilly, Sanofi, Novo Nordisk, as well as major PBMs such as CVS Caremark and OptumRx. According to court filings, these companies allegedly coordinated to increase the cost of insulin products by more than 1,000% since the mid-2000s. Despite the fact that insulin costs less than $2 per dose to manufacture, prices reportedly rose from around $20 to between $300 and $700 or more, with no changes to the drug itself.
Role of Pharmacy Benefit Managers in Insulin Cost Increases
The lawsuit claims the insulin manufacturers funneled some of their inflated profits to PBMs in exchange for favorable placement on prescription drug plans, commonly referred to as "formularies." In a purported quid pro quo arrangement, these PBMs, starting around 2012, also began to exclude competing insulin products from their formularies to maximize profits. This practice allegedly granted PBMs significant control over which drugs are accessible to most Pennsylvanians with diabetes and set the stage for widespread insulin price inflation throughout the state's healthcare system.
Impact on Consumers and Legal Remedies Sought
Attorney General Sunday is seeking restitution for Pennsylvanians affected by these price hikes, as well as injunctive relief under state consumer protection law. The lawsuit charges the defendants with deceptive business practices and calls for civil penalties of $1,000 for each violation of the Unfair Trade Practices and Consumer Protection Law, rising to $3,000 for violations involving senior citizens aged 60 or older. The complaint maintains that both diabetic patients and payors in Pennsylvania who purchased insulin during the period of inflation were directly harmed by the alleged scheme.
Context: Previous Lawsuits and Efforts to Lower Insulin Costs
This move follows a similar lawsuit filed earlier in 2024 by Philadelphia District Attorney Larry Krasner, which targeted many of the same pharmaceutical companies and PBMs. The year also saw companies like Eli Lilly and Novo Nordisk announce significant reductions in insulin prices after facing intense public and government scrutiny. Additionally, the Inflation Reduction Act, which came into effect for seniors on Medicare in 2023, capped monthly insulin costs at $35, offering some price relief to a segment of the population.
Ongoing Debate Over Drug Pricing Reform
The Pennsylvania lawsuit places renewed focus on ongoing national debates over diabetes medication prices, insulin price caps, and broader drug pricing reform. Sunday’s major legal action may serve as a significant test of consumer protection law in the context of alleged pharma collusion impacting vulnerable patient communities.
Source: phillyvoice.com.
